Mitsuhiro Kida

Dr. Mitsuhiro Kida


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2019 in World Journal of Gastroenterology
Verified
Journal Article
Open access
CKChonlada Krutsri
Chonlada Krutsri
MKMitsuhiro Kida
Mitsuhiro Kida
HYHiroshi Yamauchi
Hiroshi Yamauchi
TITomohisa Iwai
Tomohisa Iwai
HIHiroshi Imaizumi
Hiroshi Imaizumi
WKWasaburo Koizumi
Wasaburo Koizumi
Endoscopic retrograde cholangiopancreatography (ERCP) in patients with surgically altered anatomy must be performed by a highly experienced endoscopist. The challenges are accessing the afferent limb in different types of reconstruction, cannulating a papilla with a reverse orientation, and performing therapeutic interventions with uncommon endoscopic accessories. The development of endoscopic techniques has led to higher success rates in this group of patients. Device-assisted ERCP is the endoscopic procedure of choice for high success rates in short-limb reconstruction; however, these success rate is lower in long-limb reconstruction. ERCP assisted by endoscopic ultrasonography is now popular because it can be performed independent of the limb length; however, it must be performed by a highly experienced and skilled endoscopist. Stent deployment and small stone removal can be performed immediately after ERCP assisted by endoscopic ultrasonography, but the second session is needed for other difficult procedures such as cholangioscopy-guided electrohydraulic lithotripsy. Laparoscopic-assisted ERCP has an almost 100% success rate in long-limb reconstruction because of the use of a conventional side-view duodenoscope, which is compatible with standard accessories. This requires cooperation between the surgeon and endoscopist and is suitable in urgent situations requiring concomitant cholecystectomy. This review focuses on the advantages, disadvantages, and outcomes of various procedures that are suitable in different situations and reconstruction types. Emerging new techniques and their outcomes are also discussed.

6 April 2017 in Digestive Endoscopy
Verified
Journal Article
Closed access
PDF file
MKMitsuhiro Kida
Mitsuhiro Kida
YKYusuke Kawaguchi
Yusuke Kawaguchi
EMEiji Miyata
Eiji Miyata
RHRikiya Hasegawa
Rikiya Hasegawa
TKToru Kaneko
Toru Kaneko
WKWasaburo Koizumi
Wasaburo Koizumi

13 March 2012 in Digestive Endoscopy
Verified
Journal Article
Closed access
PDF file
LRLong Rong
Long Rong
MKMitsuhiro Kida
Mitsuhiro Kida
HYHiroshi Yamauchi
Hiroshi Yamauchi
KOKousuke Okuwaki
Kousuke Okuwaki
SMShiro Miyazawa
Shiro Miyazawa
WKWasaburo Koizumi
Wasaburo Koizumi

9 August 2011 in Endoscopy
Verified
Journal Article
Closed access
PDF file
MKMitsuhiro Kida
Mitsuhiro Kida
MAM. Araki
M. Araki
SMS. Miyazawa
S. Miyazawa
HIH. Ikeda
H. Ikeda
HKH. Kikuchi
H. Kikuchi
WKW. Koizumi
W. Koizumi
Background and study aim: A prototype forward-viewing instrument has been developed for therapeutic endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA). We had the opportunity to use this forward-viewing echo endoscope and to study its clinical usefulness, mainly for diagnostic EUS-FNA. Patients and methods: The prototype forward-viewing echo endoscope was used for 15 months between November 2006 and March 2010, in a study group comprising 47 consecutive patients. Diagnostic EUS-FNA was done in 38 patients and the diagnostic accuracy of the forward-viewing device was compared with that from an oblique-viewing echo endoscope in reference patients who were matched by disease and puncture route. Therapeutic EUS was done in nine patients (pseudocyst drainage in six; celiac ganglia neurolysis, biliary drainage, and pancreatic duct drainage in one each). Results: Diagnostic EUS-FNA provided a correct diagnosis in 97.4 % (37/38 patients), which was not significantly different from the 94.7 % (36/38) in the reference patients. Lesions considered difficult to access with an oblique-viewing scope, such as those located at the fornix, or the head of the pancreas, or associated with strictures, were easily punctured, as were those located at the body or tail of the pancreas or at the porta hepatis. Treatment was successful in all nine patients who underwent therapeutic EUS procedures. None of the 47 patients had any complications. Conclusions: A forward-viewing echo endoscope that allows target sites to be punctured more perpendicularly with minimal effort, can be used for diagnostic EUS-FNA and this may be advantageous, depending on the site of target lesions.

4 October 2011 in Endoscopy
Verified
Journal Article
Closed access
PDF file
MKMitsuhiro Kida
Mitsuhiro Kida
SMS. Miyazawa
S. Miyazawa
TIT. Iwai
T. Iwai
HIH. Ikeda
H. Ikeda
MTM. Takezawa
M. Takezawa
WKW. Koizumi
W. Koizumi
Background and study aims: Recent progress in chemotherapy has prolonged the survival of patients with malignant biliary strictures, leading to increased rates of stent occlusion. Occlusion of covered metallic stents now occurs in about half of all patients with malignant biliary strictures. The removal of metallic stents followed by placement of a second stent has been attempted, but outcomes remain controversial. The aim of the current study was to evaluate the effectiveness and safety of the primary placement and secondary placement (re-intervention) of covered metallic stents and to assess the feasibility and safety of stent removal. Patients and methods: The study included 186 patients with unresectable malignant biliary strictures who underwent primary stent placement between October 2001 and March 2010. Covered biliary self-expandable metal stents (SEMSs) were removed in 39 of these patients, and 36 underwent re-intervention. The patency times, occlusion rates of the first stent and re-intervention, success rates of stent removal, and complications were investigated. Results: Covered SEMSs were placed in 186 patients. The median patency time of the first stent was 352 days. Stent occlusion occurred in 48.9 % of the patients and was mainly caused by debris or food residue (37 %), dislocation (19 %), and migration with hyperplasia (19 %). Stent removal was attempted in 50 patients and was successful without complication in 39 (78 %). Most of the patients in whom stent removal was unsuccessful had migration with hyperplasia. The median patency time of the second stent was 263 days. The stent patency time did not significantly differ between the first and the second stent. Conclusions: Covered SEMSs could be safely removed at the time of stent occlusion. Patency rates were similar for initial stent placement and re-intervention.

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
SKShuko Koizumi
Shuko Koizumi
MKMitsuhiro Kida
Mitsuhiro Kida
HYHiroshi Yamauchi
Hiroshi Yamauchi
KOKosuke Okuwaki
Kosuke Okuwaki
TITomohisa Iwai
Tomohisa Iwai
WKWasaburo Koizumi
Wasaburo Koizumi
To evaluate the efficacy of doubling time (DT) of gastrointestinal submucosal tumors (GIST). From April 1987 through November 2012, a total of 323 patients were given a final histopathological diagnosis of GISTs on surgical resection or endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Kitasato University East Hospital or Kitasato University Hospital. We studied 53 of these patients (34 with resected tumors and 19 with unresected tumors) whose tumors could be measured on EUS on at least two successive occasions. The histopathological diagnosis was GIST in 34 patients, leiomyoma in 5, schwannoma in 3, ectopic pancreas in 1, hamartoma in 1, cyst in 1, Brunner’s adenoma in 1, and spindle-cell tumor in 7. We retrospectively calculated the DT of GISTs on the basis of the time course of EUS findings to estimate the growth rate of such tumors. The DT was 17.2 mo for GIST, as compared with 231.2 mo for leiomyoma, 104.7 mo for schwannoma, 274.9 mo for ectopic pancreas, 61.2 mo for hamartoma, 49.0 mo for cyst, and 134.7 mo for Brunner’s adenoma. The GISTs were divided into risk classes on the basis of tumor diameters and mitotic figures (Fletcher’s classification). The classification was extremely low risk or low risk in 28 patients, intermediate risk in 3, and high risk in 3. DT of GIST according to risk was 24.0 mo for extremely low-risk plus low-risk GIST, 17.1 mo for intermediate-risk GIST, and 3.9 mo for high-risk GIST. DT of GIST was significantly shorter than that of leiomyoma plus schwannoma (P < 0.05), and DT of high-risk GIST was significantly shorter than that of extremely low-risk plus low-risk GIST (P < 0.05). For GIST, a higher risk grade was associated with a significantly shorter DT. Small SMTs should initially be followed up within 6 mo after detection.